Page 2 - Small Molecules News Today

The collaboration will tap into the potential of artificial intelligence to design and optimize crop protection chemistry, developing a novel sustainable Mode-of-Action broad-spectrum herbicide...

Researchers utilized an untargeted metabolomics technique to look for new compounds and pathways that may contribute to residual cardiovascular disease risk.

The Canada pharmaceutical market size and share is currently valued at USD 48.62 billion in 2023. It is anticipated to generate an estimated revenue of USD 88.11 billion by 2032, according to the latest study by Polaris Market Research. Besides, the report notes that the market exhibits a robust 6.9% Compound Annual Growth Rate (CAGR) over the forecasted timeframe, 2024-2032. The key market players include AbbVie, AstraZeneca, Eli Lilly, F. Hoffmann-La Roche, GlaxoSmithKline, Johnson & John...

Cell death is fundamental to life and, thus, healthy aging. In the realm of cellular biology, ferroptosis (a form of programmed cell death) has emerged not only as a focal point of research for its potential in eliminating cancer cells, but also its role in a plethora of other diseases, including neurodegenerative diseases such as Alzheimer's disease, eye diseases such as Retinitis pigmentosa and age-related macular degeneration, as well as ischemia, cardiovascular disease, liver disease, ac...

The intricate relationship that exists between humans and the gut microbiome has become a hot research topic, and scientists are constantly uncovering new reasons why a healthy diet can lead to a healthier life.

Study evaluates senolytic CAR T-cell therapy targeting uPAR-positive cells in aged mice, showing its effectiveness in mitigating age-related metabolic dysfunction and offering a potential long-lasting treatment for aging-associated conditions.

Lonza said on Friday Chairman Albert Baehny will step down in May after six years in the job, in a second senior management reshuffle in recent months as the Swiss contract drug manufacturer grapples...

Lonza Group AG Key word Annual Results Lonza Delivers Solid 2023 Performance with 109% CER Sales Growth and 298% CORE EBITDA Margin 26Jan2024 0650 CETCEST Release of an ad hoc announcement pursuant t

Lonza Group AG / Key word: Annual Results Lonza Delivers Solid 2023 Performance with 10.9% CER Sales Growth and 29.8% CORE EBITDA Margin 26-Jan-2024 / 06:50 CET/CEST Release of an ad hoc...

Lonza said on Friday Chairman Albert Baehny will step down in May after six years in the job, in a second senior management reshuffle in recent months as the Swiss contract drug manufacturer grapples...